Advances in the Management of Cutaneous Toxicities of Targeted Therapies
April 2012
in “
Seminars in Oncology
”
EGFR inhibitors VEGFR inhibitors KIT inhibitors PDGFR inhibitors BCR-ABL inhibitors mTOR inhibitors papulopustular rash paronychia xerosis hair changes mucositis edema rashes pruritus alopecia anti-angiogenic agents sorafenib sunitinib pazopanib hand-foot-skin reaction subungual splinter hemorrhages erythematous rashes epidermal growth factor receptor inhibitors vascular endothelial growth factor receptor inhibitors platelet-derived growth factor receptor inhibitors mammalian target of rapamycin inhibitors skin rash nail infection dry skin hair loss mouth inflammation swelling itching anti-angiogenic drugs Nexavar Sutent Votrient hand-foot syndrome nail bed hemorrhages red rashes
Studysummary This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on doi.org →